Superworth

Bicycle Therapeutics BCYC

Drug Manufacturers - General, Healthcare
$3.62
−1.09%
Market cap
$253.7M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
3.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$83.5M
+195% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−69.8%

Bicycle Therapeutics trades at 3.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $83.5M over the last twelve months, up 195% on a year earlier.

Charts

Financials

Income statement for BCYC, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$5.3M+67%$19.5M+299%$9.4M−18%$2.7M−50%$3.7M−30%$10M−49%$2.9M−69%$11.7M+339%$48M+1193%$887K−91%$629K−79%$34.1M+190%
R&D$44.7M+81%$34.9M+8%$40.1M+1%$48.3M+21%$49.8M+11%$59.1M+69%$71M+77%$58.4M+21%$51.8M+4%$48.9M−17%$41.2M−42%$33.4M−43%
SG&A$14.9M+39%$16.4M+13%$15.9M+8%$18.3M+12%$21.6M+45%$21.1M+29%$18.5M+16%$18.9M+3%$20.9M−3%$17.5M−17%$14M−24%$14.1M−25%
−$54.2M+68%−$31.7M−24%−$46.6M+8%−$63.8M+26%−$67.7M+25%−$70.2M+121%−$86.6M+86%−$65.6M+3%−$24.7M−64%−$65.5M−7%−$54.6M−37%−$13.5M−79%
Interest expense$820K−1%$821K+2%$824K+0%$33K−96%$52K−94%$51K−94%$54K−93%$44K+33%$57K+10%$48K−6%$44K−19%$45K+2%
Pre-tax income−$48.8M+61%−$26.9M−32%−$39.7M−8%−$54.3M+14%−$52.9M+9%−$61.8M+130%−$79.2M+100%−$58.9M+9%−$18.9M−64%−$60.7M−2%−$50.2M−37%−$9.3M−84%
$320K−$350K−43%$115K−$3.4M−$1.1M−$1.1M+211%−$231K$205K$1.3M$172K$90K$1.2M+470%
Net income−$49.1M+64%−$26.6M−32%−$39.8M−7%−$50.8M+2%−$51.9M+6%−$60.8M+129%−$79M+98%−$59.1M+16%−$20.2M−61%−$60.8M+0%−$50.3M−36%−$10.5M−82%
−$1.16+15%−$0.62−52%−$0.77−45%−$0.74−41%−$0.75−35%−$0.88+42%−$1.14+48%−$0.85+15%−$0.29−61%−$0.87−1%−$0.72−37%−$0.15−82%
42.4M+43%42.6M+42%52M+72%69M+74%69.1M+63%69.2M+63%69.3M+33%69.3M+1%69.4M+1%69.7M+1%69.8M+1%70M+1%

Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

R&D: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

Income tax: Q1 FY19: 6 months less the 3 months printed beside them.

Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.

EPS, diluted: 6 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Bicycle Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BCYCBicycle Therapeutics$253.7Mn/mn/a3.0×+195%n/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
Peer median$508.6M11.4×13.5×1.4×+7%13.6%

More on Bicycle Therapeutics

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .